Cardiologists and vascular surgeons from Allegheny General Hospital announced Monday that they had done the first successful implant in Pittsburgh of a new device to treat patients with progressive heart failure.

The device, an alternative therapy for patients who are not responding well to medication, works by stimulating the nervous system to improve heart function. Excela Health in Westmoreland County is also using the device, it announced last fall. It is available for use at other hospitals as well.

Much like a pacemaker, the device, called Barostim, is implanted near the collarbone. It delivers electrical pulses to an area of the carotid artery typically responsible for regulating blood flow and stress hormone release. In patients with heart failure, signals in this area can become weak and put the heart under more pressure. When the device stimulates this area of the carotid artery, it targets special cells called baroreceptors, which communicate with the brain to reduce the level of stress hormones circulating through the blood. This leads to a reduction in blood pressure and alleviates stress on the heart.

Barostim was created by Minneapolis-based company CVRx. The Food and Drug Administration approved it in 2019, with a “Breakthrough Device Designation,” because of its ability to treat life-threatening conditions in populations that are not otherwise eligible for other heart failure treatments, like cardiac resynchronization therapy (CRT), in which a pacemaker is implanted to ensure the left and right sides of the heart work in tandem. The FDA based its approval on a clinical study led by physicians at the Medical University of South Carolina and other institutions, where doctors implanted Barostim into patients and measured whether their exercise capacity and quality of life improved.

Advertise with us

AHN doctors participated in the study, which led to the first FDA-approved implantation of the device in Pittsburgh in early September.

Around 6 million Americans suffer from heart failure, a condition that can occur from a combination of factors and underlying conditions like diabetes, high blood pressure, obesity or heart disease. According to the Pennsylvania Department of Health, the rate of death from heart disease in Allegheny County is higher than that of Pennsylvania as a whole.

Getting a Barostim device implanted takes about an hour, said Dr. Srinivas Murali, an AHN cardiologist specializing in heart failure, system chairman of the Department of Cardiovascular Medicine at AHN and a professor of medicine at Drexel University who oversaw the product’s implementation. The device doesn’t require hardware to be placed in the heart, and implantation can be done as an outpatient procedure, said Dr. Murali.

“We can customize device settings to each patient to get the best response,” Dr. Murali added, including adjusting settings such as the frequency of stimulation.

Liz Galle, vice president of global clinical research at CVRx, said the company is excited to see AHN’s success with the implantation.

Advertise with us

“These are patients who really have an unmet need, so we are very excited to be able to fulfill this unmet need,” she said.

Ms. Galle said Barostim was first implanted in a person with heart failure in 2011 for a European clinical trial. The device received CE mark approval for heart failure in Europe in 2014. CE mark approval, similar to FDA approval in the U.S., means a product has met health, safety and environmental requirements in the European Union. CVRx has also been in partnership with Allegheny General Hospital to further Barostim research for about 10 years.

There are different types of heart failure, categorized by a measure of how much blood the heart releases in one beat, called the ejection fraction. Some people with heart failure have a reduced ejection fraction, which means their hearts deliver less blood to the body. There are about two million people in that category, who could be eligible for the Barostim device.

Patients with high blood pressure who haven’t responded well to medication would also be eligible because Barostim reduces blood pressure. Dr. Murali said that although researchers have found that Barostim can improve hypertension management, they are still looking into whether it increases life expectancy.

Dr. Murali stressed that medication management comes first with heart failure treatment, and that patients should be on the approved heart failure medications before seeking a Barostim implantation.

Advertise with us

Researchers are also studying whether the device would be useful with other types of heart failure, such as in people with normal ejection fractions but who have stiff hearts, meaning their hearts cannot relax properly and let in enough blood.

“As more and more patients get implanted, we’re going to learn more. And that’s exciting,” Ms. Galle said. “It’s been a long journey.”

Hanna Webster: hwebster@post-gazette.com